The approach for the Plastid Company is to produce great quantities of plastids or mini cells in the plants. There are millions of these cells in each plant and they will function as efficient bio factories. The proteins will be used by research laboratories, the health service, the feed and fish industries and the pharmaceutical industry.
In addition to standard proteins Plastid will also design and produce new proteins and enzymes in demand by the market.
The production of proteins in plastids has until now been difficult, partly because it is a complicated process to put a gene into a plastid and then make a plant grow from this single plant cell.
By applying our procedures we get the right plant after two to three months. The aim is to shorten the process to one to two months. When we have the plant which produces the protein demanded by the customer, we can simply expand – we will just grow more plants. Møller says.
The Plastid Company can develop products adapted to all illnesses caused by defective proteins. A particularly interesting area is the so-called kinases, proteins which are active in transmission of signals in our body. Defect kinases cause around 400 different serious illnesses from cancer to neurological ailments.
One example is stomach cancer where a special kinase is always switched on. Stomach cancer patients therefore need inhibitors of this kinase. They must be developed continuously since our patients become resistant to inhibitors after a while, Møller explains.
We want to produce kinases in our system which may be used for developing new inhibitors for these patients. We have already managed to produce a kinase, even though this is a process in which success is not easily achieved. It shows that we are able to manage this within our patented system. There is a large market for new proteins in the industry, but the infrastructure has so far been expensive. Plastid's system is robust and the production can easily be increased or reduced, Møller says.
Silje Stangeland | alfa
Mass spectrometry sheds new light on thallium poisoning cold case
14.12.2018 | University of Maryland
Protein involved in nematode stress response identified
14.12.2018 | University of Illinois College of Agricultural, Consumer and Environmental Sciences
What if, instead of turning up the thermostat, you could warm up with high-tech, flexible patches sewn into your clothes - while significantly reducing your...
A widely used diabetes medication combined with an antihypertensive drug specifically inhibits tumor growth – this was discovered by researchers from the University of Basel’s Biozentrum two years ago. In a follow-up study, recently published in “Cell Reports”, the scientists report that this drug cocktail induces cancer cell death by switching off their energy supply.
The widely used anti-diabetes drug metformin not only reduces blood sugar but also has an anti-cancer effect. However, the metformin dose commonly used in the...
A research team from the University of Zurich has developed a new drone that can retract its propeller arms in flight and make itself small to fit through narrow gaps and holes. This is particularly useful when searching for victims of natural disasters.
Inspecting a damaged building after an earthquake or during a fire is exactly the kind of job that human rescuers would like drones to do for them. A flying...
Over the last decade, there has been much excitement about the discovery, recognised by the Nobel Prize in Physics only two years ago, that there are two types...
What if a sensor sensing a thing could be part of the thing itself? Rice University engineers believe they have a two-dimensional solution to do just that.
Rice engineers led by materials scientists Pulickel Ajayan and Jun Lou have developed a method to make atom-flat sensors that seamlessly integrate with devices...
12.12.2018 | Event News
10.12.2018 | Event News
06.12.2018 | Event News
14.12.2018 | Physics and Astronomy
14.12.2018 | Health and Medicine
14.12.2018 | Life Sciences